Understanding Wegovy vs Mounjaro Dose Differences & UK Pricing
Why Wegovy Dose Appears Lower Than Mounjaro: The Science Behind Different Mechanisms
The question of why Wegovy dose is lower than Mounjaro stems from comparing two fundamentally different molecular compounds. Wegovy contains semaglutide, a selective GLP-1 receptor agonist with a molecular weight of 4,113 daltons, whilst Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist weighing 4,813 daltons. These aren't simply different strengths of the same medicine—they're entirely separate active ingredients with distinct mechanisms of action. Wegovy's maximum dose of 2.4mg provides targeted GLP-1 receptor activation, whilst Mounjaro's 15mg delivers dual-pathway hormone stimulation through both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Understanding why Wegovy dose is lower than Mounjaro requires recognising that milligram comparisons between different active pharmaceutical ingredients are meaningless. It's comparable to asking why paracetamol 500mg differs from aspirin 300mg—the numbers reflect optimised dosing for each specific compound's pharmacological profile. Both prescription-only medicines undergo rigorous dose-finding studies to establish their therapeutic ranges, with Wegovy's 2.4mg representing the optimal balance of efficacy and tolerability for semaglutide, whilst Mounjaro's 15mg serves the same purpose for tirzepatide's dual-receptor mechanism.
UK Pricing Comparison: Wegovy vs Mounjaro Costs With Discount Codes
When examining why Wegovy dose is lower than Mounjaro alongside UK pricing, both treatments offer similar value propositions through EverydayMeds' discount code system. Wegovy starts at £79.99 for the 0.25mg starter dose (weeks 1-4) with code FIRST40 for new customers, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Mounjaro follows a comparable pricing structure with its own dose escalation schedule. Both treatments require gradual dose increases over 16-20 weeks, making bundle options like our Intro Trio (£299.99) or Progress Duo (£189.99) valuable for continuous supply management.
Returning customers benefit from discount code DOSE25 applied at checkout, whilst new customers use FIRST40 to access these competitive rates. The pricing reflects each treatment's unique manufacturing requirements and clinical development costs, rather than simple milligram-per-pound calculations. Both Wegovy and Mounjaro represent significant pharmaceutical investments in GLP-1 pathway research, with costs reflecting their prescription-only medicine status and specialist manufacturing requirements through our GPhC-registered pharmacy (#9012878).
Clinical Evidence: STEP Trials vs SURMOUNT Studies
The clinical evidence explaining why Wegovy dose is lower than Mounjaro comes from separate trial programmes designed for each treatment's specific mechanism. Wegovy's STEP trials demonstrated that 2.4mg semaglutide achieved approximately 15% average weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The STEP programme established 2.4mg as the optimal maintenance dose for semaglutide's GLP-1-only mechanism.
Mounjaro's SURMOUNT trials separately established 15mg tirzepatide as the optimal dose for its dual GLP-1/GIP mechanism, with different trial populations and methodologies. These separate development programmes mean direct dose comparisons aren't clinically meaningful—each represents the culmination of extensive pharmacokinetic and pharmacodynamic research for its specific active ingredient and mechanism of action.
How Wegovy's GLP-1 Mechanism Determines Its Optimal Dosing
Understanding why Wegovy dose is lower than Mounjaro requires appreciating how GLP-1 receptor agonists like semaglutide function in weight management. Wegovy mimics the natural hormone glucagon-like peptide-1, binding selectively to GLP-1 receptors in the brain's appetite control centres and throughout the gastrointestinal system. This selective targeting means relatively small doses can produce significant physiological effects—the 2.4mg maintenance dose provides sustained GLP-1 receptor activation for seven days through Wegovy's extended-release formulation. The dose escalation from 0.25mg to 2.4mg over 16 weeks allows patients to adapt gradually to increased GLP-1 activity, minimising gastrointestinal side effects whilst building tolerance to the therapeutic dose.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing either Wegovy or Mounjaro to understand why Wegovy dose is lower than Mounjaro begins with our 3-minute online clinical assessment, designed to evaluate your suitability for prescription weight management treatment. Our qualified prescribers review your medical history, current medications, and weight management goals within 3 working days (or 24 hours with express review), determining which treatment and starting dose suits your individual circumstances. Once approved, both treatments ship via next-day delivery using temperature-controlled cold-chain logistics to maintain pharmaceutical integrity. Our GPhC-registered pharmacy team (#9012878) provides ongoing support throughout your dose escalation journey, whether you're starting with Wegovy's 0.25mg or Mounjaro's equivalent initial dose. Payment processing includes automatic application of discount codes FIRST40 or DOSE25 at checkout, ensuring you access competitive pricing without additional steps.
Storage and Practical Considerations: Temperature Requirements
Both treatments explaining why Wegovy dose is lower than Mounjaro share similar storage requirements, though Wegovy offers superior travel convenience with 6 weeks room temperature stability versus Mounjaro's 21-day limit. Both must be stored at 2-8°C in the refrigerator before first use, using the original carton to protect from light exposure. Wegovy's FlexTouch pen design provides intuitive dose selection and injection, with pre-filled pens containing exactly four doses of your prescribed strength. The dose escalation schedule requires different pen strengths every 4 weeks initially, making bundle purchases practical for maintaining continuous treatment supply. Each pen includes built-in safety features and dose confirmation windows, ensuring accurate administration whether you're using 0.25mg starter doses or 2.4mg maintenance injections.
Dose Escalation Strategies: Why Lower Starting Doses Matter
The question of why Wegovy dose is lower than Mounjaro extends to understanding why both treatments start with minimal doses before reaching maintenance levels. Wegovy's 0.25mg starting dose represents approximately 10% of the final 2.4mg maintenance dose, allowing gradual adaptation to GLP-1 receptor stimulation. This conservative approach minimises common side effects like nausea, vomiting, and gastrointestinal upset that can occur when GLP-1 activity increases too rapidly. The 4-week intervals between dose increases provide sufficient time for physiological adaptation and side effect assessment.
Both treatments prioritise patient comfort and treatment adherence through gradual escalation, recognising that sustainable weight management requires long-term commitment rather than aggressive initial dosing. This approach explains why neither Wegovy nor Mounjaro can be prescribed at maintenance doses immediately—the lower starting doses serve essential tolerability and safety functions regardless of the final therapeutic dose required.
Making Your Choice: Professional Guidance and Discount Access
Determining whether Wegovy's lower dosing profile suits your needs better than Mounjaro's higher maintenance dose requires professional medical guidance rather than simple dose comparisons. Our prescriber team evaluates factors including your medical history, previous weight management attempts, current medications, and personal preferences to recommend the most appropriate treatment option. Both Wegovy and Mounjaro are available from EverydayMeds with identical support services, discount code access, and delivery options—your prescriber can help determine which mechanism and dosing schedule align with your weight management goals. Starting your assessment today with discount codes FIRST40 (new customers) or DOSE25 (returning customers) ensures you access competitive pricing while receiving expert clinical guidance throughout your treatment journey. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment and discover which prescription weight management option suits your individual circumstances best.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
